Resumen
Surgical resection is the standard of care for malignant adnexal cancers of the skin. The efficacy of radiotherapy and targeted therapies is still undetermined in both adjuvant and palliative settings. In routine clinical practice, genetic abnormalities are rarely assessed, although numerous mutations have been described, e.g., in TP53 (tumor protein p53), FAT2 (FAT atypical cadherin 2), KMT2D (lysine methyltransferase 2D), CACNA1S (calcium voltage-gated channel subunit alpha1 S), and PTEN (phosphatase and tensin homolog). These cancers occur mainly in the middle-aged, and are locally aggressive, but when metastasized result in poor prognosis. The aim of this study is to analyze treatment efficacy in patients treated at a reference center since 2009. The role of multidisciplinary treatment is also discussed.